Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Prospective Open Label Study of Pertuzumab, Trastuzumab, and Nab-Paclitaxel in Patients With HER-2 Positive Advanced Breast Cancer

NCT01730833 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT01730833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01730833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Prospective Open Label Study of Pertuzumab, Trastuzumab, and Nab-Paclitaxel in Patients With HER-2 Positive Advanced Breast Cancer
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Completed
Start date
July 17, 2013
Completion date
April 20, 2026
Enrollment
63 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast adenocarcinoma, her2-positive breast cancer, inflammatory breast carcinoma, recurrent breast cancer, stage iia breast cancer, stage iib breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer, stage iv breast cancer